GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Small and Large Bowel/Factors associated with symptom relief in patients with irritable bowel syndrome
124

Factors associated with symptom relief in patients with irritable bowel syndrome

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2025

The study identifies several demographic, lifestyle, psychological, and physiological factors associated with symptom relief in patients with irritable bowel syndrome (IBS). Here’s a detailed breakdown of the findings:


1. Demographic Factors

  • Age: The average age of the cohort was 45 years, but specific age-related differences in symptom relief were not highlighted.
  • Gender: Females had a slightly higher likelihood of symptom relief (54.5%) compared to males (45.9%). This could be due to gender differences in stress response, hormonal influences, or healthcare-seeking behavior.
  • IBS Subtype:
  • Patients with mixed-type IBS (IBS-M) showed the highest likelihood of symptom relief (55%) compared to diarrhea-predominant IBS (IBS-D, 39.9%) and constipation-predominant IBS (IBS-C, 40.5%).
  • The variability in symptoms in IBS-M may allow for greater responsiveness to interventions.

2. Lifestyle Factors

  • Exercise:
  • Daily exercise (≥30 minutes of moderate-intensity activity) was a strong predictor of symptom relief, with a 65.5% relief rate compared to 35% in those who did not exercise.
  • A dose-response relationship was observed, with patients exercising 3–5 times per week also showing significant benefit (53% relief rate).
  • Smoking and Alcohol Consumption:
  • While these were associated with worse baseline symptom severity, they were not directly linked to symptom relief rates. However, lifestyle counseling may help reduce the overall symptom burden.

3. Psychological Factors

  • Depression:
  • Lower depression scores were significantly associated with better symptom outcomes (OR = 0.93). Depression worsens gut-brain axis function, contributing to IBS severity, so addressing mental health is critical.
  • Stress:
  • High stress levels were associated with lower symptom relief rates (39%) compared to those with low stress (58%). Stress likely exacerbates IBS through hormonal and autonomic dysregulation.
  • Anxiety:
  • Anxiety showed some association with symptom relief in univariate analysis but lost significance in multivariate analysis, suggesting that depression and stress play stronger roles in symptom outcomes.

4. Social and Family Support

  • Family Support:
  • Strong family support was associated with a higher relief rate (60.5%) compared to those with poor support (35%). Family involvement likely enhances treatment adherence, coping, and psychological well-being.

5. Baseline Symptom Severity

  • Symptom Severity:
  • Patients with higher baseline symptom severity were more likely to report symptom relief (OR = 1.20). This may reflect greater motivation to adhere to treatment and lifestyle changes, or possibly a regression-to-the-mean effect.

6. Physiological and Biological Markers

  • CRP Levels and Gut Microbiota Diversity:
  • Neither C-reactive protein (CRP) levels nor gut microbiota diversity were independent predictors of symptom relief. While these markers are relevant to IBS pathophysiology, their role in predicting symptom improvement appears limited.

7. Medication Adherence

  • Adherence:
  • Higher medication adherence showed a trend toward better outcomes, though it was not statistically significant. This indicates that lifestyle and psychological factors may have a stronger influence on symptom relief than medication alone.

8. Financial and Economic Factors

  • Financial Stress:
  • Financial burden did not significantly impact symptom relief outcomes. This suggests that psychosocial support and coping mechanisms may outweigh economic factors in determining IBS symptom improvement.

9. Predictive Model Performance

  • The predictive model, which included factors like symptom severity, exercise, depression, stress, and family support, had an area under the curve (AUC) of 0.76, indicating good reliability in predicting symptom relief.

Clinical Implications

  • IBS management should take a holistic approach that integrates:
  • Lifestyle interventions: Regular physical activity (e.g., daily or 3–5 times/week).
  • Mental health support: Addressing depression and stress through therapy or stress management techniques.
  • Social support: Encouraging family involvement to improve adherence and coping.
  • These low-cost, non-pharmacological strategies can complement pharmacological or dietary therapies to enhance patient outcomes.

Summary of Key Predictors of Symptom Relief

  1. Positive Predictors:
  • Daily exercise (≥30 minutes of moderate-intensity activity).
  • Strong family support.
  • Lower depression and stress levels.
  • Higher baseline symptom severity.
  1. Negative Predictors:
  • High stress levels.
  • Poor family support.
  • Lack of regular physical activity.
  1. Non-Significant Predictors:
  • CRP levels and gut microbiota diversity.
  • Financial stress.
  • Anxiety (in multivariate analysis).

By focusing on these factors, healthcare providers can develop more personalized and effective IBS management plans.

Related Q&A

01

For Refractory Faecal Incontinence, Biofeedback Matches Injection at Lower Cost: CGH | October 2026

What Did the Study Find? The five-centre FIT trial enrolled adults experiencing at least four faecal-incontinence episodes over two weeks despite medical and behavioural therapy. Two hundred nonresponders—176...

02

FIT-Positive but No Colorectal Cancer: Frontline Gastroenterology | October 2026

What Did the Study Find? This real-world study followed 1,056 symptomatic FIT-positive patients without colorectal cancer (CRC) to evaluate alternative diagnoses and their relationship with faecal haemoglobin concentrations....

03

DENEB Blood Test Detects Both Colorectal Cancer and Advanced Adenomas—But Is Not Screening-Ready: The Lancet Gastroenterology & Hepatology | October 2026

What Did the Study Find? DENEB developed a blood assay combining 19 cell-free and 20 exosomal microRNAs, measured by RT-qPCR and interpreted using locked machine-learning models. Biomarkers were...

04

FMT as First-Line Therapy for Checkpoint-Inhibitor Colitis: Cell Reports Medicine | October 2026

What Did the Study Find? This early-phase study evaluated first-line fecal microbiota transplantation (FMT) in 13 patients with cancer who developed grade ≥2 immune checkpoint inhibitor–mediated diarrhea and...

05

“Nonadvanced” Adenomas Are Not One Risk Category: Gastroenterology | October 2026

What Did the Study Find? Investigators studied 16,870 adults aged 50–75 years who underwent at least two colonoscopies between 2004 and 2023. During a median 5.3 years, five-year...

06

New US Guidance Defines How to Diagnose, Clear and Survey Serrated Polyposis Syndrome: Gastroenterology | 30 September 2026

What Did the Guideline Find? The Task Force recommends diagnosing serrated polyposis syndrome using the 2019 WHO cumulative-lifetime criteria, making accurate documentation of every serrated lesion’s number, size...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer